arrow
Z

Zinaida Good

Parker Institute for Cancer Immunotherapy
H指数:17
被引数:4,296

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In vivo genome-wide CRISPR screens of human T cells in solid tumours

实体瘤中人类T细胞的体内全基因组CRISPR筛选

Nature
IF48.5
2026-08-120
PRE
Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

通过捕捉键工程克服T细胞对肿瘤自身抗原的耐受性

Science
IF45.8
2026-03-190
PRE
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer

泛血液学癌症对嵌合抗原受体 (CAR) T细胞治疗反应的预测生物标志物

2026-03-090
PRE
HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA

人源化抗CAR抗体影响弥漫性中线胶质瘤中GD2-CAR T细胞的持久应答

2025-11-010
OAAI
SINGLE-CELL LANDSCAPE OF B7H3-CAR T THERAPY IN GLIOMA: MECHANISMS OF RESISTANCE AND SIGNATURES OF LONG-TERM RESPONSE

单细胞景观揭示B7H3-CAR T疗法在胶质瘤中的抗药机制及长期应答特征

2025-11-010
PRE
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma

CSF1R⁺髓系-单核细胞驱动侵袭性B细胞淋巴瘤中CAR-T细胞的耐药性

2025-06-120
OAAI
MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA
2024-11-110
PRE
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-speci fi c expansion and toxicity
2024-06-258
OAAI
Engineered CD47 protects T cells for enhanced antitumour immunity

工程CD47保护T细胞增强抗肿瘤免疫

Nature
IF48.5
2024-05-150
OAAI
Lineage tracing defines responding CAR T cells in patients with B cell malignancies
2024-03-220
PRE
Lineage tracing of CAR T cells in patients with B cell malignancies
2023-04-040
PRE
Immune signatures of GD2 CAR T cell activity in H3K27M+diffuse midline glioma patients
2023-04-040
PRE
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
2022-09-12116
OA
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

GD2-CAR T细胞治疗H3K27M-mutated弥漫性中线胶质瘤

Nature
IF48.5
2022-02-070
OAAI